Monoclonal antibodies for tumors

Monoclonal Antibodies for Tumors

Monoclonal antibodies (mAbs) are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance, or mimic the immune system's attack on cancer cells. They are designed to bind to specific targets found on cancer cells. With their high specificity, monoclonal antibodies have become a pivotal component in the treatment of various tumors, offering a targeted approach to cancer therapy.

Overview

Monoclonal antibodies are a form of immunotherapy, which works by harnessing the power of the body's immune system to fight cancer. They are created by cloning a single white blood cell (hence "monoclonal"), resulting in antibodies that are identical and targeted against a specific protein on the surface of cancer cells.

Mechanism of Action

The mechanism of action of monoclonal antibodies in treating tumors involves several strategies:

• Targeting growth factors: Some mAbs work by blocking the ability of cancer cells to grow and divide by inhibiting growth factor receptors.
• Immune system modulation: Certain mAbs can enhance the immune system's ability to recognize and destroy cancer cells.
• Delivering radiation or chemotherapy: Some monoclonal antibodies are conjugated with a radioactive substance or a chemotherapeutic drug, acting as a delivery system to bring these agents directly to the cancer cells.
• Inducing apoptosis: Some mAbs can induce apoptosis (programmed cell death) directly in cancer cells.

Types of Monoclonal Antibodies

Monoclonal antibodies can be categorized based on their source and structure:

• Murine: These are made entirely from mouse proteins and are the least used in cancer treatment due to the potential for human immune system rejection.
• Chimeric: These antibodies are a combination of mouse and human protein sequences, reducing the immune response compared to murine antibodies.
• Humanized: These contain a greater proportion of human sequences, further reducing the likelihood of immune rejection.
• Fully human: Produced using recombinant DNA technology, these antibodies are completely human, minimizing immune system rejection.

Applications in Cancer Treatment

Monoclonal antibodies have been approved for the treatment of a wide range of cancers, including but not limited to:

• Breast cancer
• Colorectal cancer
• Lymphoma
• Melanoma
• Lung cancer

Examples of Monoclonal Antibodies

• Trastuzumab (Herceptin): Used for treating HER2-positive breast cancer.
• Rituximab (Rituxan): Used for treating certain types of lymphoma.
• Cetuximab (Erbitux): Used for treating colorectal cancer and head and neck cancer.
• Ipilimumab (Yervoy): Used for treating melanoma.

Challenges and Considerations

While monoclonal antibodies have revolutionized cancer treatment, there are challenges and considerations, including:

• Resistance: Cancer cells may develop resistance to mAbs, necessitating combination therapies.
• Side effects: Though generally less severe than chemotherapy, mAbs can cause immune-related side effects.
• Cost: The production and development of monoclonal antibodies can be expensive, impacting their accessibility.

Future Directions

Research is ongoing to develop new monoclonal antibodies, improve existing ones, and discover novel targets for therapy. Combination therapies involving mAbs and other treatments such as chemotherapy, radiation therapy, and other immunotherapies are also being explored to enhance efficacy and overcome resistance.

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian